

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

NCT06978400

Status	RECRUITING
Phase	Phase 2
Sponsor	Blokhin's Russian Cancer Research Center
Enrollment	64 participants

Plain Language Summary

This study is testing a combination of targeted cancer drugs — dabrafenib plus cetuximab or panitumumab (antibody therapies) — added to standard FOLFOX chemotherapy as a first-line treatment for people with metastatic colorectal cancer that has a specific genetic mutation called BRAF V600E.

****You may be eligible if...****

- You have metastatic colorectal cancer that has the BRAF V600E mutation
- Your cancer does not have MSI-H or dMMR status
- You have not yet received chemotherapy for your metastatic disease
- Your primary tumor has been removed or is not causing symptoms
- You are in good overall health (ECOG 0 to 2)
- You have measurable disease on a scan

****You may NOT be eligible if...****

- You have received more than 2 lines of treatment for colorectal cancer
- You have another active cancer
- You are pregnant or breastfeeding
- You have HIV
- Your life expectancy is less than 3 months

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (10)

- Histologically confirmed colorectal adenocarcinoma that contains MSS and BRAF V600E mutation
- Metastatic inoperable colorectal cancer
- Adequate function of hematopoiesis and basic indicators of internal organs
- Has measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors (RECIST v1.1).
- Lacking antitumor systemic treatment for colorectal cancer.

... and 5 more (see full listing online)

Exclusion (7)

- Participants having more than 2 lines of treatment (a progression of disease within 12 months of the completion of adjuvant and/or perioperative chemotherapy with oxaliplatin and fluoropyrimidines is acceptable).
- Presence of any other malignancy, except radically treated basal cell carcinoma, cervical cancer in situ, currently or within 5 years prior to enrolment.
- Pregnant and breastfeeding women.

• Male and female patients with preserved reproductive potential who refused to use adequate contraception throughout the study.
<https://clinicaltrials.gov/study/NCT06978400>
• HIV-infected patients.

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

... and 2 more (see full listing online)

Locations (1 total)

Blokhin's Russian Cancer Research Center, Moscow, Russia

<https://clinicaltrials.gov/study/NCT06978400>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by ClinicalTrialsFinder.org.